logo
Plus   Neg
Share
Email

Allergan: Atogepant Shows Robust Efficacy, Safety In Phase 2b/3 Trial

Allergan plc (AGN) announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant, a highly potent CGRP receptor antagonist in development for the prevention of migraine. The company said all active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically significant reduction from baseline in monthly migraine/probable migraine headache days in patients with episodic migraine treated with atogepant compared with placebo for 12 weeks.

In the CGP-MD-01 trial, atogepant was well tolerated. There was no signal of hepatotoxicity with atogepant in the study with daily administration over 12 weeks. The liver safety profile for atogepant was similar when compared to placebo.

Allergan said the company will continue with its phase 3 program for atogepant following discussions with regulatory authorities.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. (WMT) reported adjusted EPS of $1.41 for the fourth-quarter of fiscal 2019. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $1.33 for the quarter. Analysts' estimates typically exclude special items. Net income attributable to Walmart... Anglo-Australian miner BHP, formerly known as BHP Billiton, reported Tuesday higher attributable profit in its first half, while revenues were flat. Underlying EBITDA margin was lower. Further, the company maintained its dividend. Looking ahead, the company said its productivity for the 2019 financial year is now expected to be broadly flat. Asia-focused lender HSBC Holdings Plc reported Tuesday higher profit in its fiscal 2018 reflecting revenue growth in all of global businesses, despite a challenging fourth quarter. Further, the company said it reported a good start to 2019, noting that Group revenue performance in January was ahead of plan for the month. In London, HSBC shares were losing around 4 percent in the morning trading.
Follow RTT